|1.||Minkowitz, Harold S: 6 articles (08/2015 - 03/2013)|
|2.||Evashenk, Mark A: 5 articles (08/2015 - 03/2013)|
|3.||Palmer, Pamela P: 5 articles (08/2015 - 03/2013)|
|4.||Benhamou, D: 5 articles (01/2013 - 05/2000)|
|5.||Fourcade, Olivier: 4 articles (01/2015 - 08/2007)|
|6.||Minville, Vincent: 4 articles (01/2015 - 08/2007)|
|7.||Safavi, Mohammadreza: 3 articles (04/2015 - 01/2008)|
|8.||Honarmand, Azim: 3 articles (04/2015 - 01/2008)|
|9.||Gu, Er-Wei: 3 articles (02/2015 - 07/2012)|
|10.||Chiang, Yu-Kun: 3 articles (01/2015 - 03/2013)|
10/01/1997 - "Intrathecal (i.t.) sufentanil provides rapid effective pain relief for early labor, but it also produces undesirable side effects, which may be primarily related to cephalad spread. "
07/01/2012 - "A nonrandomized, open-label dose trial to determine safety and efficacy of intranasal sufentanil in patients with a distal extremity injury who presented to the ED with moderate to severe pain was conducted. "
10/01/2010 - "In this study we studied the efficacy of intraoperative-intrathecal sufentanil injection versus placebo on post operative pain management. "
07/01/2014 - "The long-term safety and efficacy of intrathecal therapy using sufentanil in chronic intractable non-malignant pain."
11/01/2014 - "Secondary outcome measures were: pain at rest and during flexion of the knee, worst pain experienced during a 5-m walk, patient's evaluation of muscle strength during walk, and amount of sufentanil administered during the 90-min study period. "
05/01/1996 - "These results suggest that preinjury i.v. sufentanil is not more beneficial for postoperative pain control than the postinjury administration."
11/01/1994 - "Plasma concentration of sufentanil at the different time points varied from 0.021 to 0.142 ng/ml, with a mean maximal peak concentration of 0.103 ng/ml. The plasma concentration 48 hours after injection varied from 0.026 to 0.074 ng/ml. Although an IM injection of sufentanil in thin vegetable oil is effective for postoperative pain relief, it is associated with wide interindividual variability in plasma concentration of sufentanil and long duration of action."
03/01/2001 - "We evaluated the efficacy of intraarticular sufentanil in the prevention of postoperative pain after day-case arthroscopic procedures. "
01/01/2015 - "This study evaluates the efficacy and safety of a sufentanil sublingual tablet system (SSTS) for the management of postoperative pain following open abdominal surgery. "
01/01/2015 - "Sufentanil sublingual tablet system for the management of postoperative pain following open abdominal surgery: a randomized, placebo-controlled study."
10/01/1999 - "We have previously shown that intrathecal sufentanil was effective for ESWL, but was associated with a high incidence of itching. "
02/01/2006 - "This study aimed at evaluating different therapeutic options to prevent itching after spinal sufentanil. "
04/01/2015 - "Due to their same efficacy in the treatment of intrathecal sufentanil-induced pruritus, they can be widely used in clinical practice."
05/01/2014 - "Only pruritus as a side effect was significantly higher in the sufentanil group (P < 0.05), while all other evaluated side effects were significantly lower in the sufentanil group (P < 0.05). "
07/01/2011 - "Pruritus was significantly more frequent in patients receiving spinal sufentanil (Groups 3 and 4 vs. Groups 1 and 2). "
07/01/2014 - "There was no statistical difference in the operation time, the sufentanil dosage, VAS score, the incidence of postoperative nause- a and vomiting among the three groups (P > 0.05). "
05/01/1988 - "However, patients given sufentanil, 4.5 micrograms/kg, had a higher incidence of vomiting in the recovery room and during the first postoperative day. "
03/01/1993 - "Those receiving sufentanil made fewer PCA requests but had a significantly greater incidence of vomiting during the infusion and dizziness after the termination of the infusion. "
07/01/2014 - "Sufentanil consumption (41.50±21.80 vs. 89.70±35.22 μg; P<0.01) after 48 hours, time to bowel recovery (1.80±0.70 vs. 3.15±1.04 d; P<0.01), incidence of nausea and vomiting (1.75±0.72 vs. 2.40±0.68; P<0.05), and mean length of hospitalization (5.6±2.44 vs. 7.35±2.85 d; P<0.01) were significantly reduced, and the sedation score and liver function change were also comparable between the 2 groups. "
06/03/2014 - "Group A had lower VAS than group B at 1, 4, 8, 12, 24 h after surgery (P < 0.05), less PCA demand (2.9 ± 1.6 vs 9.1 ± 1.8) (P < 0.05) and less PCA sufentanil consumption((69.1 ± 5.8)µg vs (92.6 ± 6.9)µg) (P < 0.05), thus less post-operative nausea or vomiting and higher satisfaction (P < 0.05). "
|5.||Postoperative Nausea and Vomiting (PONV)
05/01/2008 - "Continuous infusion of sufentanil promoted better postoperative pain control with decreased consumption of rescue analgesic and, consequently, reduced incidence of PONV and reduced time of stay in the recovery room."
07/01/1989 - "The incidence of postoperative nausea, vomiting and other side effects was not higher and discharge times were not longer after sufentanil compared to the placebo group. "
08/01/2007 - "Epidural naloxone was effective in reducing PONV induced by epidural sufentanil and additionally enhanced the analgesic effect. "
03/01/1996 - "Midazolam causes more nasal irritation during instillation, and sufentanil causes more postoperative nausea and vomiting. "
02/01/1992 - "The incidence of postoperative nausea and vomiting: a retrospective comparison of alfentanil versus sufentanil."
|2.||Bupivacaine (Bupivacaine Hydrochloride)
|4.||Morphine (MS Contin)
|7.||Clonidine (ST 155)
|4.||Patient-Controlled Analgesia (Analgesia, Patient Controlled)